Biotech Spotlight: Genprex, Inc. (GNPX) has recently captured attention on X due to its advancements in gene therapy research. Many users are discussing the potential impact of upcoming financial results and business updates. The buzz suggests a keen interest in how these developments might influence the stock's future.
Clinical Data Excitement: Conversations on X also focus on positive preclinical data related to Genprex’s work in cancer treatment. There’s notable curiosity about presentations at recent conferences that highlighted promising results. Some speculate this could be a catalyst for significant stock movement.
Market Watch: Recent posts on X mention a spike in trading activity and price fluctuations following the company’s news releases. Discussions reflect a mix of optimism and caution as investors weigh the speculative nature of a company with no revenue yet. The chatter keeps the stock on many traders’ radar.
Note: This discussion summary was generated from an AI condensation of post data.
Genprex, Inc. Congressional Stock Trading
Members of Congress have traded $GNPX stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GNPX stock by members of Congress over the last 6 months:
- REPRESENTATIVE TIM MOORE has traded it 2 times. They made 2 purchases worth up to $65,000 on 11/07, 10/29 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Genprex, Inc. Hedge Fund Activity
We have seen 3 institutional investors add shares of Genprex, Inc. stock to their portfolio, and 28 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANE STREET GROUP, LLC added 205,180 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,737,874
- UBS GROUP AG removed 127,995 shares (-97.5%) from their portfolio in Q3 2025, for an estimated $21,682
- GEODE CAPITAL MANAGEMENT, LLC removed 71,923 shares (-95.6%) from their portfolio in Q3 2025, for an estimated $12,183
- HRT FINANCIAL LP removed 46,720 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $10,647
- VIRTU FINANCIAL LLC removed 43,103 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $7,301
- FREEDOM INVESTMENT MANAGEMENT, INC. removed 16,580 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,808
- HUB INVESTMENT PARTNERS, LLC removed 15,160 shares (-97.8%) from their portfolio in Q3 2025, for an estimated $2,568
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
